… a randomized clinical trial in 1985 that compared carboplatin to cisplatin in first-line treatment
of stage … (PFS) were observed among patients treated with cisplatin alone (50 mg/m2), or in …

… cisplatin or carboplatin has significant activity in non-small-cell lung cancer (NSCLC). This
phase … paclitaxel/carboplatin combination was similar to that in patients receiving a paclitaxel/…

… The combination of moderate doses of cisplatin and carboplatin has significantly reduced …
The doses for carboplatin and cisplatin were chosen on the basis that carboplatin and cisplatin …

… Of the eight trials, seven were randomized phase III trials, 6-11,13 and the remaining one
was a randomized phase II trial. There was no placebo-controlled double-blind trial. Each of …

… randomized, multicenter, phase III trial to compare the tolerability of gemcitabine plus cisplatin
… For example, in a recently published large randomized phase III trial of NSCLC, GP was …

… as a randomized phase II study to obtain some useful information for further development in
a controlled randomized phase III … of this phase II study should be considered exploratory. …

… than that to cisplatin alone (1 1- 19% vs. zn~~1 Although the number of patients in this study
was too small to establish whether carboplatin is the ideal substitute for cisplatin in the first…

… Unlike cisplatin, however, standard doses of carboplatin (up … Thus, the substitution of
cisplatin with carboplatin may be a … -label, multicenter, randomized phase 2 trial whose primary …

… cisplatin and carboplatin. These agents have well established differences in toxicity profiles:
cisplatin … whereas the myelosuppressive effects of carboplatin lead to hematologic toxicities […

… Results from randomized phase II studies suggest that adding cetuximab to first-line … This
multicenter, noncomparative, open-label, randomized phase II study was designed to evaluate …